Clinical and pathological evidence for a frontal variant of Alzheimer disease

Permalink
https://escholarship.org/uc/item/78n319zs

Journal
Archives of Neurology, 56(10)

ISSN
0003-9942

Authors
Johnson, JK
Head, E
Kim, R
et al.

Publication Date
1999-10-01

DOI
10.1001/archneur.56.10.1233

License
CC BY 4.0

Peer reviewed
Clinical and Pathological Evidence for a Frontal Variant of Alzheimer Disease

Julene K. Johnson, PhD; Elizabeth Head, PhD; Ronald Kim, MD; Arnold Starr, MD; Carl W. Cotman, PhD

Objective: To evaluate the clinical and pathological features of a subgroup of patients with Alzheimer disease (AD) who exhibited early and disproportionately severe impairments on tests of frontal lobe functioning. We hypothesized that these patients would exhibit a greater degree of either neurofibrillary tangle (NFT) or senile plaque pathology in the frontal lobes than would patients with typical AD.

Design and Outcome Measures: We examined the neuropsychological profiles and senile plaque and NFT accumulation in the frontal, entorhinal, temporal, and parietal cortices in 3 patients with AD who exhibited disproportionate frontal impairments during early stages of dementia (frontal AD) and 3 matched patients with typical AD (typical AD).

Results: Compared with the typical AD group, the frontal AD group performed significantly worse on 2 tests of frontal lobe functioning and on the Wechsler Adult Intelligence Scale–Revised Block Design test. No significant group differences were found on other tests. Analysis of brain tissue samples demonstrated that, despite comparable entorhinal, temporal, and parietal NFT loads, the frontal AD group showed a significantly higher NFT load in the frontal cortex than the typical AD group. Senile plaque pathology in the frontal and entorhinal cortices did not differentiate the 2 groups.

Conclusions: We identified a subgroup of patients with pathologically confirmed AD who presented in the early stages of dementia with disproportionate impairments on tests of frontal lobe functioning and had a greater-than-expected degree of NFT pathology in the frontal lobes, suggesting the existence of a frontal variant of AD that has distinctive clinical and pathological features.

Arch Neurol. 1999;56:1233-1239

Alzheimer disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognition that affects multiple systems, such as memory, language, executive functions, and visuospatial skills. Throughout the course of the disease, a heterogeneous profile of preserved and impaired functions is observed, suggesting the involvement of selective cognitive systems or brain regions. This cognitive heterogeneity led researchers\(^\text{1,2}\) to postulate the existence of subgroups of patients with AD in the 1980s. That is, although most patients diagnosed with AD have multiple cognitive impairments, some patients have relatively prominent impairments in 1 cognitive domain. For example, prominent and early impairments in visuospatial skills\(^\text{3,4}\) and language\(^\text{5,6}\) have been documented in patients with histologically confirmed AD.

Although several studies have identified subgroups of patients with AD at the clinical level, only a few researchers have conducted clinicopathological studies of atypical cases. This is of particular importance because focal cognitive impairments are often associated with non-AD pathology.\(^\text{10}\) Faden and Townsend\(^\text{11}\) first described a patient with cortical blindness who later developed dementia. At autopsy, this patient showed prominent atrophy in the occipital lobe that contained numerous cortical neuritic plaques suggestive of AD. Quantitative measures of pathology, however, were not done. Hof and colleagues\(^\text{12,13}\) later described a series of 14 patients with pathologically confirmed AD who presented clinically with severe visuospatial impairments referred to as Balint syndrome. These patients had a greater-than-expected degree of neurofibrillary tangle (NFT) and neuritic plaque pathology in the occipitoparietal and...
PATIENTS AND METHODS

PATIENTS

We reviewed 63 recent, pathologically confirmed AD cases (Consortium to Establish a Registry for Alzheimer's Disease [CERAD] criteria) from the UCI Alzheimer's Disease Research Center's Tissue Repository. Of these patients, 19 (30%) had a greater degree of NFT pathology in the frontal than in the entorhinal cortex. Based on this observation, we further investigated the pathological and clinical features of a subset of patients. From the 63 patients, we then selected 16 who had well-characterized clinic visits at the UCI Alzheimer's Disease Research Center during the mild stages of dementia (Mini–Mental State Examination score ≥18). When reviewing the neuropsychological profiles, a subset of 3 patients with disproportionately severe impairments on 2 tests of frontal lobe function (ie, Trail Making Test A and FAS fluency; frontal AD group) was observed. For purposes of comparison, we selected a second group of 3 patients with “typical” AD (typical AD group) who were matched for Mini–Mental State Examination score, educational level, and extent of NFT pathology in the entorhinal cortex, in an effort to control for disease severity. Demographic information is shown in Table 1, and both groups are described further in the next sections.

CLINICAL PROFILE

All patients were clinically evaluated at the UCI Alzheimer’s Disease Research Center by a staff neurologist and neuropsychologist using standard clinical protocols (including CERAD tests) consisting of standard neurological, physical, and neuropsychological examinations; routine laboratory blood analysis; electrocardiogram; chest radiograph; family interviews; and neuroimaging (ie, magnetic resonance imaging and single photon emission computed tomography). No patients had a history of severe head injury, psychiatric disorders, or other neurological disorders.

A subset of neuropsychological tests from the standard clinical protocol was selected a priori (Table 2) to profile multiple cognitive abilities, including frontal lobe functioning, memory, visuospatial, and language skills. Measures of frontal lobe functioning included Trail Making Test A and the Controlled Oral Word Association Test (FAS fluency). Impairments on Trail Making Test A are common in patients with frontal lobe lesions and are also associated with disproportionate frontal hypometabolism. In addition, impairments on letter fluency have also been found to correlate with frontal lobe damage. The CERAD Word List task was used to measure short-term verbal memory. In addition, the 30-item version of the Boston Naming Test, CERAD Animal Naming, and the Wechsler Adult Intelligence Scale–Revised (WAIS-R) Vocabulary test were used to measure language abilities. The WAIS-R Digit Span task and the Symbol Digit Modalities Test were used to measure attention. The Kendrick Digit Copy task was used to estimate psychomotor speed. Finally, the CERAD Constructional Praxis and the WAIS-R Block Design tasks were used to profile visuospatial skills. All tests were administered and scored according to standard protocols. Age- and education-adjusted norms were applied when available.

NEUROPATHOLOGICAL STUDIES

Informed consent for the brain autopsies, approved by the UCI institutional review board, was obtained from the patient or next of kin before death. All patients were diagnosed as having AD by an Alzheimer's Disease Research Center neuropathologist (R.K.) according to CERAD criteria. No patient showed cell loss, microvacuolation, or gliosis in layers II and III of the frontal cortex typical of frontotemporal dementia (FTD). In addition, there was no evidence of Lewy body or Pick body formation. Brain tissue samples were postfixed in either 4% paraformaldehyde or 10% buffered formalin. The 50-μm-thick sections from the middle frontal gyrus (area 8), hippocampus with entorhinal cortex, inferoparietal cortex (area 7), temporal cortex (area 22), and occipital lobe (area 17) were prepared using a vibratome.

For β-amyloid immunostaining, free-floating tissue sections from each brain region were pretreated with 90% formic acid for 4 minutes, treated for 30 minutes with 3% hydrogen peroxide in 10% methanol to block endogenous peroxidase activity, and incubated overnight in polyclonal anti–β-amyloid (from B. J. Cummings at 1:500) at room temperature. For visualizing NFTs, adjacent sections were immunostained using the monoclonal anti-PhF-1 (from S. Greenberg at 1:800). Standard immunohistochemical protocols were followed as previously described.

To quantify the extent of NFT and senile plaque pathology, image analysis techniques were used. Slides of the frontal, entorhinal, inferoparietal, and temporal cortices were analyzed without previous knowledge of diagnosis using procedures described by Cummings and Cotman. Neurofibrillary tangle pathology staging was conducted using the method described by Braak and Braak. Sections of transentorhinal and entorhinal regions and hippocampus, inferoparietal, and occipital cortex were evaluated by 2 independent judges (E.H. and R.K.) who were unaware of the group assignments. Patients were assigned to I of 3 Braak and Braak stages: I/II (transentorhinal), III/IV (limbic), or V/VI (isocortical).

DATA ANALYSIS

A repeated-measures analysis of variance was used to compare the neuropsychological profiles and demographic information to determine group differences. A Scheffe test was used for all post hoc analyses. The frontal and typical AD groups were compared for differences in age, educational level, age of onset, disease duration, interval between the clinical evaluation and death, postmortem interval, and scores on the neuropsychological tests. The second analysis used independent t tests to determine whether measures of entorhinal, frontal, inferoparietal, and temporal NFT loads differed between the typical and frontal AD groups. In addition, we also conducted the same analysis to determine whether the β-amyloid loads differed in the frontal and entorhinal cortices. All statistical analyses were conducted using a software system (SAS for Windows; SAS Institute Inc, Cary, NC) and a 0.05 error level.
inferoparietal lobes. Other studies documented atypical distributions of pathology in patients with focal cognitive impairments involving language,14-17 visuospatial impairments,18,19 and praxis.20 Except for the patients studied by Hof and colleagues, all of the clinicopathological studies listed previously involved only single patients. Therefore, it is necessary to conduct additional clinicopathological studies to help understand the manner in which AD evolves.

We observed a subset of patients with clinically diagnosed AD who presented in the mild stages of dementia with prominent frontal lobe impairments. On the basis of our review of the clinical and neuropathological features of patients with pathologically confirmed AD at the University of California at Irvine (UCI) Alzheimer’s Disease Research Center’s Tissue Repository, we hypothesized that patients with disproportionate impairments of frontal lobe functioning would exhibit a greater-than-expected degree of either NFT or neuritic plaque pathology in the frontal lobes.

### RESULTS

#### DEMOGRAPHICS

No significant differences (P>.05) in educational level, sex, age of onset, disease duration, interval between clinical evaluation and death, or postmortem interval were noted between the 2 groups. A repeated-measures analysis of variance with the neuropsychological results resulted in a nonsignificant main effect of disease group. However, the task × disease group interaction was significant (F2,57 = 16.59; P<.001), suggesting that some but not all tasks were performed differently by the 2 groups. Post hoc Scheffé test results indicated that significant group differences existed on Trail Making Test A, FAS fluency, and WAIS-R Block Design.

#### NEUROPSYCHOLOGICAL PROFILE

Mean scores on the neuropsychological measures for the typical and frontal AD groups are shown in Table 2. Compared with the typical AD group, the frontal AD group performed significantly worse on Trail Making Test A (P = .002) and FAS fluency (P = .02). Scores on Trail Making Test A for the frontal AD group ranged from 100 to 167 seconds for completion and did not overlap with the typical AD group, whose scores ranged from 47 to 69 seconds. Scores on Trail Making Test A obtained by the frontal AD group were greater than 3 SD below the norm for their age and educational level, reflecting a severe impairment. In contrast, scores obtained by the typical AD group ranged from normal to a mild impairment. The frontal AD group also consistently showed below-average performance on the FAS fluency; in contrast, all patients in the typical AD group performed within the

### Table 1. Patient Demographics

<table>
<thead>
<tr>
<th>Alzheimer Disease Group</th>
<th>Typical (n = 3)</th>
<th>Frontal (n = 3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age of onset, y</td>
<td>64.7 ± 9.6</td>
<td>71.7 ± 8.1</td>
</tr>
<tr>
<td>Disease duration, y</td>
<td>6.7 ± 4.7</td>
<td>8.0 ± 2.0</td>
</tr>
<tr>
<td>Education, y</td>
<td>11.7 ± 1.5</td>
<td>13.3 ± 2.3</td>
</tr>
<tr>
<td>Men/women, No.</td>
<td>2/1</td>
<td>2/1</td>
</tr>
<tr>
<td>Evaluation to death interval, y</td>
<td>3.8 ± 1.9</td>
<td>4.8 ± 0.3</td>
</tr>
<tr>
<td>Postmortem interval, y</td>
<td>8.3 ± 6.9</td>
<td>4.2 ± 0.8</td>
</tr>
</tbody>
</table>

* Data are given as mean ± SD, unless otherwise indicated. No significant group differences were found (P>.05).

### Table 2. Neuropsychological Test Results

<table>
<thead>
<tr>
<th>Alzheimer Disease Group</th>
<th>Typical</th>
<th>Frontal</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mini–Mental State Examination</td>
<td>23.33 (20, 22, 28)</td>
<td>20.33 (18, 21, 22)</td>
<td>.33</td>
</tr>
<tr>
<td>Trail Making Test A (seconds to complete)</td>
<td>56.00 (47, 52, 69)</td>
<td>140.67 (100, 155, 167)</td>
<td>.002†</td>
</tr>
<tr>
<td>FAS fluency‡</td>
<td>40.67 (32, 45, 48)</td>
<td>18.00 (13, 17, 27)</td>
<td>.02†</td>
</tr>
<tr>
<td>WAIS-R Digit Span</td>
<td>9.00 (8, 8, 11)</td>
<td>5.67 (4, 6, 7)</td>
<td>.08</td>
</tr>
<tr>
<td>Forward digits</td>
<td>9.00 (8, 8, 11)</td>
<td>5.67 (4, 6, 7)</td>
<td>.08</td>
</tr>
<tr>
<td>Reverse digits</td>
<td>6.00 (4, 6, 8)</td>
<td>3.00 (2, 3, 4)</td>
<td>.17</td>
</tr>
<tr>
<td>Symbol Digit Modalities Test§</td>
<td>22.67 (11, 22, 35)</td>
<td>6.00 (0, 8, 10)</td>
<td>.14</td>
</tr>
<tr>
<td>CERAD Word List</td>
<td>11.00 (5, 12, 16)</td>
<td>7.33 (4, 5, 13)</td>
<td>.22</td>
</tr>
<tr>
<td>Trials 1-3 (total)</td>
<td>1.33 (0, 1, 3)</td>
<td>0.33 (0, 0, 1)</td>
<td>.33</td>
</tr>
<tr>
<td>5-min delayed recall</td>
<td>1.33 (0, 1, 3)</td>
<td>0.33 (0, 0, 1)</td>
<td>.33</td>
</tr>
<tr>
<td>Boston Naming Test (30-item version)</td>
<td>17.00 (10, 14, 27)</td>
<td>22.00 (12, 25, 29)</td>
<td>.87</td>
</tr>
<tr>
<td>CERAD Animal Naming¶</td>
<td>10.67 (8, 11, 13)</td>
<td>8.33 (2, 9, 14)</td>
<td>.21</td>
</tr>
<tr>
<td>WAIS-R Vocabulary (scaled score)</td>
<td>9.67 (8, 8, 13)</td>
<td>10.33 (7, 12, 12)</td>
<td>.96</td>
</tr>
<tr>
<td>CERAD Constructional Praxis</td>
<td>10.00 (9, 10, 11)</td>
<td>7.67 (7, 8, 8)</td>
<td>.06</td>
</tr>
<tr>
<td>WAIS-R Block Design (scaled score)</td>
<td>5.67 (5, 5, 7)</td>
<td>1.00 (1, 1, MD)</td>
<td>.01†</td>
</tr>
<tr>
<td>Kendrick Digit Copy¶</td>
<td>93.33 (80, 100, 100)</td>
<td>67.00 (43, 66, 92)</td>
<td>.29</td>
</tr>
</tbody>
</table>

* Scores are given as means (individual scores). WAIS-R indicates Wechsler Adult Intelligence Scale–Revised; CERAD, Consortium to Establish a Registry for Alzheimer’s Disease; and MD, missing data.
† Significant group differences (analysis of variance, Scheffé post hoc adjustment, P<.05).
‡ The number of words beginning with F, A, S in 1 minute.
§ The number of symbol-number pairs in 90 seconds.
¶ The number of animals in 1 minute.
† The number of numbers copied in 2 minutes.
normal range. Significant group differences were also found on the WAIS-R Block Design ($P = .01$). In contrast, no significant group differences ($P > .05$) were found on other neuropsychological tests.

**NEUROPATHOLOGICAL STUDIES**

Analysis of brain tissue samples from these patients demonstrated that, despite comparable entorhinal NFT loads, the frontal AD group showed a significantly higher NFT load ($t_4 = 14.3; P < .001$) in the frontal cortex than the typical AD group (Figure 1). In addition, there were no significant group differences in the degree of NFT pathology in the parietal ($t_4 < 1; P = .40$) or temporal ($t_4 < 1; P = .82$) cortices. Table 3 represents the individual NFT “load” values for patients in the frontal and typical AD groups. Photomicrographs taken from the frontal and entorhinal regions of a representative patient in each group also highlight the differences in NFT pathology (Figure 2). In contrast, β-amyloid pathology in the frontal and entorhinal cortices did not significantly differ between the 2 groups ($t_4 < 1; P = .37$). Likewise, all patients in both groups fell into Braak and Braak stage V/VI.

**COMMENT**

In this study, we identified a subgroup of patients with pathologically confirmed AD who presented clinically with early and disproportionate frontal lobe impairments on neuropsychological tests and exhibited an unusually high degree of frontal tangle pathology at autopsy. This finding is similar to those of other studies$^{12,13,18,19}$ that correlate focal clinical symptoms and atypical distributions of pathology in AD. Our results are also similar to those of Binetti and colleagues, who identified 7 of 35 mildly demented patients with AD with severe impairments on frontal lobe tests. Binetti et al also found no significant differences on other neuropsychological tests.

The most distinctive clinical feature of patients with frontal AD in this study was the severe impairment on tests of frontal lobe functioning during the mild stages of dementia. That is, on 2 tests that specifically measured frontal lobe function, the frontal AD group performed 3 SD below the norm and significantly worse than the typical AD group. Using the same criteria outlined in this study, we determined that 14% of patients with clinically diagnosed AD who presented to our clinic in the mild stages of dementia show a similar pattern of cognitive deficits. Compared with the typical AD group, the frontal AD group also performed significantly worse on the WAIS-R Block Design task, a finding that is typically associated with parietal damage.$^{38,39}$ However, the WAIS-R Block Design test not only involves visuospatial processing but also the sequencing of blocks into specific patterns. Patients with frontal lobe damage can also exhibit impairments on the Block Design task due to behavioral abnormalities such as inattention to details, impairments in planning, and impulsivity.$^{40}$ Thus, the impairment on Block Design may not reflect a visuospatial impairment per se.

Despite severe impairments on the tests of frontal lobe functioning, the performance of the frontal AD group on other neuropsychological tests was similar to the typical AD group. This suggests that the severe frontal impairment in these patients was the primary distinguish-

---

**Table 3. Neurofibrillary Tangle (NFT) “Load” Values for the 6 Patients**

<table>
<thead>
<tr>
<th>Area</th>
<th>FrONTAL, Patient No.</th>
<th></th>
<th></th>
<th></th>
<th>Typical, Patient No.</th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Frontal (area 8)</td>
<td>47.30</td>
<td>47.40</td>
<td>40.20</td>
<td>6.10</td>
<td>0.64</td>
<td>1.16</td>
<td></td>
</tr>
<tr>
<td>Entorhinal</td>
<td>34.30</td>
<td>19.80</td>
<td>31.10</td>
<td>20.10</td>
<td>17.36</td>
<td>21.92</td>
<td></td>
</tr>
<tr>
<td>Temporal (area 22)</td>
<td>2.62</td>
<td>1.67</td>
<td>0.75</td>
<td>2.10</td>
<td>0.30</td>
<td>2.05</td>
<td></td>
</tr>
<tr>
<td>Parietal (area 7)</td>
<td>1.18</td>
<td>1.61</td>
<td>0.29</td>
<td>3.50</td>
<td>0.27</td>
<td>2.36</td>
<td></td>
</tr>
</tbody>
</table>

*The NFT load represents the proportion of area occupied by NFT. Note that the maximal NFT burden for all 3 patients in the frontal AD group is in the frontal cortex.*

©1999 American Medical Association. All rights reserved.
Patients with frontal AD share some clinical features with other frontal dementia syndromes associated with non-AD pathology. For example, patients with FTD or frontal lobe dementia also exhibit significant impairments on tests of frontal lobe functioning. These frontal lobe syndromes, however, are typically distinguished from AD by a lack of memory and visuospatial impairments that were similar in the frontal AD group and visuospatial impairments that were similar to the frontal AD group. In addition, although the average age at onset tends to be younger in FTD, the frontal AD group had a similar age at onset to the typical AD group. Thus, although the frontal AD group exhibits some clinical features that are similar to other frontal lobe dementias, the clinical profile of the frontal AD group is more similar to that of AD.

The second distinguishing feature between the typical and frontal AD groups was the presence of an approximately 10-fold higher NFT load in the frontal cortex in the frontal AD group. Increased tangle pathology in the frontal AD group was not a reflection of disease severity; both groups were similar in terms of hippocampal NFT and Braak and Braak stage. In addition, the frontal cortex in patients with frontal AD seems to be the most severely affected of the 5 brain regions sampled, suggesting an anterior shift in NFT pathology. On the other hand, patients with typical AD showed maximal NFT pathology in the entorhinal cortex. In contrast, the degree of β-amyloid accumulation did not distinguish the groups. The frontal AD group also lacked the superficial cortical microvacuolar changes, neuronal loss, or gliosis characteristic of FTD. This dissociation strongly suggests a role for the abnormal phosphorylation of tau and the formation of NFTs in the pathogenesis of frontal lobe dysfunction in the frontal AD group. However, there may be other pathological features that contribute to frontal lobe dysfunction, and we cannot yet rule out this possibility.

The association between NFT pathology and neuropsychological deficits is consistent with other studies reporting a correlation between the severity of dementia and NFT and plaque pathology in AD. However, global tests of cognitive function such as the Mini–Mental State Examination are typically used in these analyses. Our results and those of recent studies highlight the value of using specific neuropsychological tasks to test the function of specific cortical circuits.

The reasons for the behavioral and pathological heterogeneity in AD are not yet well understood. However, several researchers hypothesized that the clinical pattern is a result of the type, location, and degree of pathology. More specifically, focal impairments may indicate specific disruption of neural circuits that subserve specific cognitive functions. Especially during the early stages of AD, the neuropathology is typically restricted to specific brain regions or networks. Neurofibrillary lesions in AD begin in the limbic and temporoparietal regions and only later progress to the frontal and occipital cortices. This predictable sequence is thought to occur with minimal individual variation. Therefore, any deviation from this projected sequence of pathological lesions is significant and may help clarify the basis for atypical presentations of AD.

In this study, an increase in tangles but not plaques was observed in the frontal AD group. This finding suggests that tangles, rather than plaques, may contribute to the atypical clinical presentation of the frontal AD group. In the other subgroups of AD described previously, both plaques and tangles were increased in the
regions of maximal pathology. It is possible that the focal deficits are indicative of a selective, early, and prominent vulnerability of certain brain regions that are typically thought to acquire pathology at a later stage in AD. In the scenario of the frontal AD patients, the disproportionate frontal NFT pathology may reflect a relative vulnerability of the frontal lobes, namely tau pathology. Thus, 2 possibilities exist: (1) NFT pathology has an earlier onset in patients with frontal AD, or (2) NFT pathology accumulates at a faster rate in patients with frontal AD. In addition, possible genetic contributions in the frontal AD group may be consistent with a recent report of tau mutations underlying a type of FTD.

This study provides evidence for the presence of a subgroup of patients with AD who present with both early and prominent frontal lobe impairments and have unusually high degrees of frontal tangle pathology at autopsy. These findings suggest the existence of a frontal variant of AD that has distinctive clinical and pathological features. Although most studies characterize the clinical and pathological features of patients with atypical AD involve only case studies, this study should be expanded with additional patients. Future studies should also attempt to investigate frontal lobe functioning with more specific tests to better characterize and test specific frontal circuits involved. It will also be important to identify patients with frontal AD to address potential clinical management issues; frontal lobe impairments are often associated with specific behavioral problems that require specialized patient management. Identification of a frontal variant of AD adds to the list of conditions that must be considered in the differential diagnosis of prominent frontal lobe dysfunction. Finally, if the cause of these forms of dementia is different from that of typical AD, this would suggest that interventions may also be different.

Accepted for publication January 22, 1999.

This study was supported by grants T32-AG00096, AG-05142, and AG-00538 from the National Institute on Aging, Bethesda, Md.

We thank Masaru H. Oshita, Institute for Brain Aging and Dementia, for help in tissue preparation and Robert Newcomb, PhD, University of California at Irvine Statistical Consulting Center, for statistical advice.

Reprints: Julene K. Johnson, PhD, Institute for Brain Aging and Dementia, University of California at Irvine, 1100 Medical Plaza, Irvine, CA 92697-4285 (e-mail: jkh@uci.edu).

REFERENCES